Antimicrobial resistance (AMR) poses a huge threat to the prevention and treatment of a growing number of infections caused by bacteria, parasites, viruses, and fungi. A public-private partnership involving nine European projects and 98 organisations is now calling for long-term investment to maintain Europe’s ability to research and develop new antibiotics.
ADVERTISEMENT
Tag Archive for: Gram-negative
Macrocycle library secialist Spexis AG is set to sell a preclinical antibiotics programme afor CHF2m to Basilea Pharmaceutica Ltd.